PBMs and health insurers decide what medicines you can get, and they set the price you pay at the pharmacy. At the same time, over half of every dollar spent on medicines goes to these middlemen and others. Find out more:
Dr. Julie Gerberding from
@Merck
shares how past experiences fighting MERS, SARS & other infectious diseases is informing our fight to combat
#COVID19
today and preparing us for the next challenge: antimicrobial resistance.
DYK 1 in 10 medicines worldwide are counterfeit? Importation schemes would open the U.S. borders to these dangerous & potentially deadly substances. Read more:
Giovanni Caforio, M.D., chairman of the board and CEO at
@bmsnews
and
@steveubl
penned an open letter about how our industry is working non-stop to find effective treatments and vaccines
.
@robzirk
shares the story of five researchers at Aspen
#SpotlightHealth
who are making a difference. "I am continuously amazed to learn about the depth of the work being done by these unsung heroes."
Wondering why your medicine costs more at the hospital? Research shows that 1 in every 5 hospitals marks up the price of medicine by at least 700%. Learn more at
There are 1,100+ medicines & vaccines in development for cancer. This new report shows how researchers are making advancements in the fight against cancer. RT if you know someone affected by this disease.
#GoBoldly
What
@WhiteHouse
isn't telling you: They're giving a single government agency power to arbitrarily set medicine prices with little accountability, oversight or input from patients & their doctors—with consequences long after this administration is gone.
Today, the Biden-Harris Administration is announcing the first 10 drugs selected for Medicare price negotiation.
Seniors paid $3.4 billion in out-of-pocket costs for these 10 drugs in 2022. President Biden’s Inflation Reduction Act is working to bring down those costs.
.
@WSJopinion
: Importing Bad Ideas on Drug Prices: The latest example is a GOP plan in Florida to import prescription drugs from Canada, which is impractical, unsafe and unlikely to reduce prices at the pharmacy.
As the biopharmaceutical industry attacks
#COVID19
in the labs,
@LillyPad
@Merck
&
@pfizer
are empowering their employees w/ medical or lab expertise to pause their roles & volunteer on the frontlines. Learn more here: via
@steveubl
Reforms can fix broken incentives and make the health care system work better for patients. PBMs and other middlemen in the supply chain should be paid a fee based on the value their services provide. Learn more at
In today’s IP Explained, we take a look at how the Hatch-Waxman Act has successfully streamlined the process for generic medicine approvals while also preserving incentives for innovation. Learn more
#intellectualproperty
We’re excited to kickoff this year’s
#AspenIdeas
with
#SpotlightHealth
! Looking forward to hear the experts and innovators at the forefront of health & medicine talk about how they
#GoBoldly
.
"The future of medical innovation in America is at a crossroads" PhRMA Pres. & CEO
@SteveUbl
writes. Speaker Pelosi’s plan threatens innovative research & is unprecedented in size & scope leading to fewer new medicines & lost hope for patients
@statnews
The biopharmaceutical industry and
@US_FDA
is committed to closing the health equity gap by addressing barriers to bring diversity to clinical trials. Learn about collaborative efforts to bring more equitable health care solutions at